Radioembolization is an established treatment modality that has been subjected to many
improvements over the last decade. Developments are occurring at a high pace, affecting …

Holmium microspheres have recently become available in the European market as the third
type of microspheres for radioembolization of unresectable liver malignancies. Holmium …

Methods for calculating the activity to be administered during yttrium-90 radioembolization (RE)
are largely based on empirical toxicity and efficacy analyses, rather than dosimetry. At …

In hepatic 90 Y radioembolization, pretreatment 99m Tc-macroaggregated albumin ( 99m Tc-MAA)
nuclear imaging is used for lung shunt analysis, evaluation of extrahepatic deposition…

Background The efficacy of radioembolisation for the treatment of liver tumours depends on
the selective distribution of radioactive microspheres to tumorous tissue. The distribution of …

Background Intra-arterial radioembolization with yttrium-90 microspheres ( 90 Y-RE) is an
increasingly used therapy for patients with unresectable liver malignancies. Over the last …

Purpose Radiation pneumonitis is a rare but serious complication of radioembolic therapy
of liver tumours. Estimation of the mean absorbed dose to the lungs based on pretreatment …

Radioembolization of liver malignancies with 166 Ho-microspheres has been shown to be
safe in a phase 1 dose-escalation study. The purpose of this study was to investigate the …

166 Ho-poly(l-lactic acid) microspheres allow for quantitative imaging with MR imaging or
SPECT for microsphere biodistribution assessment after radioembolization. The purpose of …

Purpose As an alternative to technetium-99m-macroaggregated albumin ( 99m Tc-MAA), a
scout dose of holmium-166 ( 166 Ho) microspheres can be used prior to 166 Ho-…